Biology of the major facilitative folate transporters SLC19A1 and SLC46A1

Current Topics in Membranes

Volumn 73, Issue , 2014, Pages 175-204

  Hou, Zhanjun ^a,b   Matherly, Larry H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Antifolate; Folate; Oligomerization; Proton coupled folate transporter; Reduced folate carrier; Transporter

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; PROTON COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER;

ANIMAL; CHEMISTRY; HUMAN; METABOLISM;

ANIMALS; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; PROTON-COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER PROTEIN;

EID: 84898659462     PISSN: 10635823     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800223-0.00004-9     Document Type: Chapter

References (138)

1. Abramson J., Smirnova I., Kasho V., Verner G., Kaback H.R., Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003, 301(5633):610-615.
2. Assaraf Y.G., Babani S., Goldman I.D. Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. The Journal of Biological Chemistry 1998, 273(14):8106-8111.
3. Atabay B., Turker M., Ozer E.A., Mahadeo K., Diop-Bove N., Goldman I.D. Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. Pediatric Hematology and Oncology 2010, 27(8):614-619.
4. Borzutzky A., Crompton B., Bergmann A.K., Giliani S., Baxi S., Martin M., et al. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clinical Immunology 2009, 133(3):287-294.
5. Brigle K.E., Spinella M.J., Sierra E.E., Goldman I.D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. The Journal of Biological Chemistry 1995, 270(39):22974-22979.
6. Cao W., Matherly L.H. Characterization of a cysteine-less human reduced folate carrier: Localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods. The Biochemical Journal 2003, 374(Pt 1):27-36.
7. Cao W., Matherly L.H. Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods. The Biochemical Journal 2004, 378(Pt 1):201-206.
8. Chang A.B., Lin R., Keith Studley W., Tran C.V., Saier M.H. Phylogeny as a guide to structure and function of membrane transport proteins. Molecular Membrane Biology 2004, 21(3):171-181.
9. Cherian C., Kugel Desmoulin S., Wang L., Polin L., White K., Kushner J., et al. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemotherapy and Pharmacology 2013, 71(4):999-1011.
10. Chladek J., Martinkova J., Simkova M., Vaneckova J., Koudelkova V., Nozickova M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. European Journal of Clinical Pharmacology 1998, 53(6):437-444.
11. Deng Y., Hou Z., Wang L., Cherian C., Wu J., Gangjee A., et al. Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition. Molecular Pharmacology 2008, 73(4):1274-1281.
12. Deng Y., Wang Y., Cherian C., Hou Z., Buck S.A., Matherly L.H., et al. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. Journal of Medicinal Chemistry 2008, 51(16):5052-5063.
13. Deng Y., Zhou X., Kugel Desmoulin S., Wu J., Cherian C., Hou Z., et al. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. Journal of Medicinal Chemistry 2009, 52(9):2940-2951.
14. Diop-Bove N., Jain M., Scaglia F., Goldman I.D. A novel deletion mutation in the proton-coupled folate transporter (PCFT; SLC46A1) in a Nicaraguan child with hereditary folate malabsorption. Gene 2013, 527(2):673-674.
15. Dixon K.H., Lanpher B.C., Chiu J., Kelley K., Cowan K.H. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. The Journal of Biological Chemistry 1994, 269(1):17-20.
16. Drori S., Jansen G., Mauritz R., Peters G.J., Assaraf Y.G. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. The Journal of Biological Chemistry 2000, 275(40):30855-30863.
17. Duan P., Wu J., You G. Mutational analysis of the role of GXXXG motif in the function of human organic anion transporter 1 (hOAT1). International Journal of Biochemistry and Molecular Biology 2011, 2(1):1-7.
18. Duch D.S., Banks S., Dev I.K., Dickerson S.H., Ferone R., Heath L.S., et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Research 1993, 53(4):810-818.
19. Duddempudi P.K., Nakashe P., Blanton M.P., Jansen M. The monomeric state of the proton-coupled folate transporter represents the functional unit in the plasma membrane. The FEBS Journal 2013, 280(12):2900-2915.
20. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Advanced Drug Delivery Reviews 2004, 56(8):1067-1084.
21. Ferguson P.L., Flintoff W.F. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. The Journal of Biological Chemistry 1999, 274(23):16269-16278.
22. Gibbs D.D., Theti D.S., Wood N., Green M., Raynaud F., Valenti M., et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Research 2005, 65(24):11721-11728.
23. Goldman I.D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Annals of the New York Academy of Sciences 1971, 186:400-422.
24. Goldman I.D. A model system for the study of heteroexchange diffusion: Methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochimica et Biophysica Acta 1971, 233(3):624-634.
25. Goldman I.D., Lichtenstein N.S., Oliverio V.T. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. The Journal of Biological Chemistry 1968, 243(19):5007-5017.
26. Gonen N., Assaraf Y.G. Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resistance Updates 2012, 15(4):183-210.
27. Gonen N., Assaraf Y.G. Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resistance Updates 2012, 15(4):183-210.
28. Gonen N., Bram E.E., Assaraf Y.G. PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochemical and Biophysical Research Communications 2008, 376(4):787-792.
29. Henderson G.B., Strauss B.P. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Research 1990, 50(6):1709-1714.
30. Henderson G.B., Zevely E.M. Transport of methotrexate in L1210 cells: Effect of ions on the rate and extent of uptake. Archives of Biochemistry and Biophysics 1980, 200(1):149-155.
31. Henderson G.B., Zevely E.M. Anion exchange mechanism for transport of methotrexate in L1210 cells. Biochemical and Biophysical Research Communications 1981, 99(1):163-169.
32. Henderson G.B., Zevely E.M. Structural requirements for anion substrates of the methotrexate transport system in L1210 cells. Archives of Biochemistry and Biophysics 1983, 221(2):438-446.
33. Henderson G.B., Zevely E.M. Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochemistry International 1983, 6(4):507-515.
34. Hou Z., Cherian C., Drews J., Wu J., Matherly L.H. Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. The Journal of Biological Chemistry 2010, 285(7):4732-4740.
35. Hou Z., Kugel Desmoulin S., Etnyre E., Olive M., Hsiung B., Cherian C., et al. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. The Journal of Biological Chemistry 2012, 287(7):4982-4995.
36. Hou Z., Matherly L.H. Oligomeric structure of the human reduced folate carrier: Identification of homo-oligomers and dominant-negative effects on carrier expression and function. The Journal of Biological Chemistry 2009, 284(5):3285-3293.
37. Hou Z., Stapels S.E., Haska C.L., Matherly L.H. Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. The Journal of Biological Chemistry 2005, 280(43):36206-36213.
38. Hou Z., Wu J., Ye J., Cherian C., Matherly L.H. Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking. The Biochemical Journal 2010, 430(2):265-274.
39. Hou Z., Ye J., Haska C.L., Matherly L.H. Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. The Journal of Biological Chemistry 2006, 281(44):33588-33596.
40. Huang Y., Lemieux M.J., Song J., Auer M., Wang D.N. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003, 301(5633):616-620.
41. Inoue K., Nakai Y., Ueda S., Kamigaso S., Ohta K.Y., Hatakeyama M., et al. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. American Journal of Physiology. Gastrointestinal and Liver Physiology 2008, 294(3):G660-G668.
42. Jacques P.F., Selhub J., Bostom A.G., Wilson P.W., Rosenberg I.H. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. The New England Journal of Medicine 1999, 340(19):1449-1454.
43. Jansen G. Receptor-and carrier-mediated transport systems for folates and antifolates. Antifolate drugs in cancer therapy 1999, 293-321. Humana Press Inc, Totowa, NJ. A.L. Jackman (Ed.).
44. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. The Journal of Biological Chemistry 1998, 273(46):30189-30198.
45. Kamen B.A., Smith A.K. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Advanced Drug Delivery Reviews 2004, 56(8):1085-1097.
46. Kugel Desmoulin S., Hou Z., Gangjee A., Matherly L.H. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biology & Therapy 2012, 13(14):1355-1373.
47. Kugel Desmoulin S., Wang L., Hales E., Polin L., White K., Kushner J., et al. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Molecular Pharmacology 2011, 80(6):1096-1107.
48. Kugel Desmoulin S., Wang L., Hales E., Polin L., White K., Kushner J., et al. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Molecular Pharmacology 2011, 80(6):1096-1107.
49. Kugel Desmoulin S., Wang L., Polin L., White K., Kushner J., Stout M., et al. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Molecular Pharmacology 2012, 82(4):591-600.
50. Kugel Desmoulin S., Wang Y., Wu J., Stout M., Hou Z., Fulterer A., et al. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Molecular Pharmacology 2010, 78(4):577-587.
51. Kuhnel J.M., Chiao J.H., Sirotnak F.M. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. Journal of Cellular Physiology 2000, 184(3):364-372.
52. Lasry I., Berman B., Glaser F., Jansen G., Assaraf Y.G. Hereditary folate malabsorption: A positively charged amino acid at position 113 of the proton-coupled folate transporter (PCFT/SLC46A1) is required for folic acid binding. Biochemical and Biophysical Research Communications 2009, 386(3):426-431.
53. Lasry I., Berman B., Straussberg R., Sofer Y., Bessler H., Sharkia M., et al. A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function. Blood 2008, 112(5):2055-2061.
54. Liu X.Y., Matherly L.H. Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: Evidence for a charge-pair association. The Biochemical Journal 2001, 358(Pt 2):511-516.
55. Liu X.Y., Matherly L.H. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochimica et Biophysica Acta 2002, 1564(2):333-342.
56. Liu X.Y., Witt T.L., Matherly L.H. Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: Role of the transmembrane domain 6/7 linker region in reduced folate carrier function. The Biochemical Journal 2003, 369(Pt 1):31-37.
57. Lu S.C. S-Adenosylmethionine. The International Journal of Biochemistry & Cell Biology 2000, 32(4):391-395.
58. Lucock M. Folic acid: Nutritional biochemistry, molecular biology, and role in disease processes. Molecular Genetics and Metabolism 2000, 71(1-2):121-138.
59. 2+ transport and uncoupled fluxes. Pflügers Archiv 2006, 451(4):544-558.
60. Mahadeo K.M., Diop-Bove N., Ramirez S.I., Cadilla C.L., Rivera E., Martin M., et al. Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico. The Journal of Pediatrics 2011, 159(4):623-627.
61. Mahadeo K., Diop-Bove N., Shin D., Unal E.S., Teo J., Zhao R., et al. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. American Journal of Physiology. Cell Physiology 2010, 299(5):C1153-C1161.
62. Marchant J.S., Subramanian V.S., Parker I., Said H.M. Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in mammalian epithelial cells. The Journal of Biological Chemistry 2002, 277(36):33325-33333.
63. Matherly L.H. Human reduced folate carrier gene and transcript variants: Functional, physiologic, and pharmacologic consequences. Current Pharmacogenetics 2004, 2:287-298.
64. Matherly L.H., Czajkowski C.A., Angeles S.M. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Research 1991, 51(13):3420-3426.
65. Matherly L.H., Goldman D.I. Membrane transport of folates. Vitamins and Hormones 2003, 66:403-456.
66. Matherly L.H., Hou Z. Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitamins and Hormones 2008, 79:145-184.
67. Matherly L.H., Hou Z., Deng Y. Human reduced folate carrier: Translation of basic biology to cancer etiology and therapy. Cancer Metastasis Reviews 2007, 26(1):111-128.
68. Menter A., Thrash B., Cherian C., Matherly L.H., Wang L., Gangjee A., et al. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: Evidence for a mechanism involving the proton-coupled folate transporter. The Journal of Pharmacology and Experimental Therapeutics 2012, 342(3):696-708.
69. Meyer E., Kurian M.A., Pasha S., Trembath R.C., Cole T., Maher E.R. A novel PCFT gene mutation (p.Cys66LeufsX99) causing hereditary folate malabsorption. Molecular Genetics and Metabolism 2010, 99(3):325-328.
70. Min S.H., Oh S.Y., Karp G.I., Poncz M., Zhao R., Goldman I.D. The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. The Journal of Pediatrics 2008, 153(3):435-437.
71. Moscow J.A., Gong M., He R., Sgagias M.K., Dixon K.H., Anzick S.L., et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Research 1995, 55(17):3790-3794.
72. Nakai Y., Inoue K., Abe N., Hatakeyama M., Ohta K.Y., Otagiri M., et al. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. The Journal of Pharmacology and Experimental Therapeutics 2007, 322(2):469-476.
73. Polgar O., Ierano C., Tamaki A., Stanley B., Ward Y., Xia D., et al. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry (Mosc) 2010, 49(10):2235-2245.
74. Prasad P.D., Ramamoorthy S., Leibach F.H., Ganapathy V. Molecular cloning of the human placental folate transporter. Biochemical and Biophysical Research Communications 1995, 206(2):681-687.
75. Qiu A., Jansen M., Sakaris A., Min S.H., Chattopadhyay S., Tsai E., et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 127(5):917-928.
76. Qiu A., Min S.H., Jansen M., Malhotra U., Tsai E., Cabelof D.C., et al. Rodent intestinal folate transporters (SLC46A1): Secondary structure, functional properties, and response to dietary folate restriction. American Journal of Physiology. Cell Physiology 2007, 293(5):C1669-C1678.
77. Rizwan A.N., Burckhardt G. Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research 2007, 24(3):450-470.
78. Rosowsky A., Bader H., Wright J.E., Keyomarsi K., Matherly L.H. Synthesis and biological activity of N omega-hemiphthaloyl-alpha, omega-diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin. Journal of Medicinal Chemistry 1994, 37(14):2167-2174.
79. Roy K., Tolner B., Chiao J.H., Sirotnak F.M. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. The Journal of Biological Chemistry 1998, 273(5):2526-2531.
80. Sadlish H., Williams F.M., Flintoff W.F. Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. The Biochemical Journal 2002, 364(Pt 3):777-786.
81. Salojin K.V., Cabrera R.M., Sun W., Chang W.C., Lin C., Duncan L., et al. A mouse model of hereditary folate malabsorption: Deletion of the PCFT gene leads to systemic folate deficiency. Blood 2011, 117(18):4895-4904.
82. Schron C.M., Washington C., Blitzer B.L. The transmembrane pH gradient drives uphill folate transport in rabbit jejunum. Direct evidence for folate/hydroxyl exchange in brush border membrane vesicles. The Journal of Clinical Investigation 1985, 76(5):2030-2033.
83. Sharina I.G., Zhao R., Wang Y., Babani S., Goldman I.D. Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Molecular Pharmacology 2001, 59(5):1022-1028.
84. Sharina I.G., Zhao R., Wang Y., Babani S., Goldman I.D. Role of the C-terminus and the long cytoplasmic loop in reduced folate carrier expression and function. Biochemical Pharmacology 2002, 63(9):1717-1724.
85. Shayeghi M., Latunde-Dada G.O., Oakhill J.S., Laftah A.H., Takeuchi K., Halliday N., et al. Identification of an intestinal heme transporter. Cell 2005, 122(5):789-801.
86. Shin D.S., Mahadeo K., Min S.H., Diop-Bove N., Clayton P., Zhao R., et al. Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Molecular Genetics and Metabolism 2011, 103(1):33-37.
87. Shin D.S., Min S.H., Russell L., Zhao R., Fiser A., Goldman I.D. Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood 2010, 116(24):5162-5169.
88. Shin D.S., Zhao R., Fiser A., Goldman I.D. Role of the fourth transmembrane domain in proton-coupled folate transporter function as assessed by the substituted cysteine accessibility method. American Journal of Physiology. Cell Physiology 2013, 304(12):C1159-C1167.
89. Shin D.S., Zhao R., Yap E.H., Fiser A., Goldman I.D. A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. American Journal of Physiology. Cell Physiology 2012, 302(9):C1405-C1412.
90. Sierra E.E., Brigle K.E., Spinella M.J., Goldman I.D. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochemical Pharmacology 1997, 53(2):223-231.
91. Sierra E.E., Goldman I.D. Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochemical Pharmacology 1998, 55(9):1505-1512.
92. Sirotnak F.M., Chello P.L., Moccio D.M., Kisliuk R.L., Combepine G., Gaumont Y., et al. Stereospecificity at carbon 6 of fomyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochemical Pharmacology 1979, 28(19):2993-2997.
93. Sirotnak F.M., Donsbach R.C. Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 Leukemia cells. Cancer Research 1974, 34(2):371-377.
94. Sirotnak F.M., Kurita S., Hutchison D.J. On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Research 1968, 28(1):75-80.
95. Stokstad E.L.R. Historical perspective on key advances in the biochemistry and physiology of folates. Contemporary issues in clinical nutrition: Folic acid metabolism in health and disease 1990, 1-21. Wiley-Liss, New York. M.F. Picciano, E.L.R. Stokstad, J.F. Greogory (Eds.).
96. Subramanian V.S., Marchant J.S., Said H.M. Apical membrane targeting and trafficking of the human proton-coupled transporter in polarized epithelia. American Journal of Physiology. Cell Physiology 2008, 294(1):C233-C240.
97. Umapathy N.S., Gnana-Prakasam J.P., Martin P.M., Mysona B., Dun Y., Smith S.B., et al. Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types. Investigative Ophthalmology & Visual Science 2007, 48(11):5299-5305.
98. Unal E.S., Zhao R., Chang M.H., Fiser A., Romero M.F., Goldman I.D. The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1. The Journal of Biological Chemistry 2009, 284(26):17846-17857.
99. Unal E.S., Zhao R., Goldman I.D. Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. American Journal of Physiology. Cell Physiology 2009, 297(1):C66-C74.
100. Unal E.S., Zhao R., Qiu A., Goldman I.D. N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT). Biochimica et Biophysica Acta 2008, 1778(6):1407-1414.
101. Urquhart B.L., Gregor J.C., Chande N., Knauer M.J., Tirona R.G., Kim R.B. The human proton-coupled folate transporter (hPCFT): Modulation of intestinal expression and function by drugs. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010, 298(2):G248-G254.
102. Visentin M., Zhao R., Goldman I.D. The antifolates. Hematology/Oncology Clinics of North America 2012, 26(3):629-648.
103. Visentin M., Zhao R., Goldman I.D. Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate. Molecular Pharmacology 2012, 82(2):209-216.
104. Wang L., Cherian C., Kugel Desmoulin S., Mitchell-Ryan S., Hou Z., Matherly L.H., et al. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. Journal of Medicinal Chemistry 2012, 55(4):1758-1770.
105. Wang L., Cherian C., Kugel Desmoulin S., Polin L., Deng Y., Wu J., et al. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. Journal of Medicinal Chemistry 2010, 53(3):1306-1318.
106. Wang L., Kugel Desmoulin S., Cherian C., Polin L., White K., Kushner J., et al. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. Journal of Medicinal Chemistry 2011, 54(20):7150-7164.
107. Wang Y., Zhao R., Russell R.G., Goldman I.D. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochimica et Biophysica Acta 2001, 1513(1):49-54.
108. Wessels J.A., Huizinga T.W., Guchelaar H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(3):249-255.
109. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Molecular Pharmacology 1995, 48(3):459-471.
110. Whetstine J.R., Flatley R.M., Matherly L.H. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: Identification of seven non-coding exons and characterization of a novel promoter. The Biochemical Journal 2002, 367(Pt 3):629-640.
111. White J.C., Bailey B.D., Goldman I.D. Lack of stereospecificity at carbon 6 of methyltetrahydrofolate transport in Ehrlich ascites tumor cells. Carrier-mediated transport of both stereoisomers. The Journal of Biological Chemistry 1978, 253(1):242-245.
112. Williams F.M., Flintoff W.F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. The Journal of Biological Chemistry 1995, 270(7):2987-2992.
113. Williams F.M., Murray R.C., Underhill T.M., Flintoff W.F. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. The Journal of Biological Chemistry 1994, 269(8):5810-5816.
114. Witt T.L., Stapels S.E., Matherly L.H. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: Localization of a substrate binding domain to transmembrane domains 7-12. The Journal of Biological Chemistry 2004, 279(45):46755-46763.
115. Wollack J.B., Makori B., Ahlawat S., Koneru R., Picinich S.C., Smith A., et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. Journal of Neurochemistry 2008, 104(6):1494-1503.
116. Wong S.C., Proefke S.A., Bhushan A., Matherly L.H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. The Journal of Biological Chemistry 1995, 270(29):17468-17475.
117. Wong S.C., Zhang L., Proefke S.A., Matherly L.H. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochimica et Biophysica Acta 1998, 1375(1-2):6-12.
118. Wong S.C., Zhang L., Witt T.L., Proefke S.A., Bhushan A., Matherly L.H. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. The Journal of Biological Chemistry 1999, 274(15):10388-10394.
119. Xia W., Low P.S. Folate-targeted therapies for cancer. Journal of Medicinal Chemistry 2010, 53(19):6811-6824.
120. Yang C.H., Sirotnak F.M., Dembo M. Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: Directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. The Journal of Membrane Biology 1984, 79(3):285-292.
121. Yang J., Vlashi E., Low P. Folate-linked drugs for the treatment of cancer and inflammatory diseases. Sub-Cellular Biochemistry 2012, 56:163-179.
122. Zhao R., Assaraf Y.G., Goldman I.D. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. The Journal of Biological Chemistry 1998, 273(30):19065-19071.
123. Zhao R., Diop-Bove N., Visentin M., Goldman I.D. Mechanisms of membrane transport of folates into cells and across epithelia. Annual Review of Nutrition 2011, 31:177-201.
124. Zhao R., Gao F., Babani S., Goldman I.D. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clinical Cancer Research 2000, 6(8):3304-3311.
125. Zhao R., Gao F., Goldman I.D. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochemical Pharmacology 1999, 58(10):1615-1624.
126. Zhao R., Gao F., Hanscom M., Goldman I.D. A prominent low-pH methotrexate transport activity in human solid tumors: Contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clinical Cancer Research 2004, 10(2):718-727.
127. Zhao R., Gao F., Wang Y., Diaz G.A., Gelb B.D., Goldman I.D. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. The Journal of Biological Chemistry 2001, 276(2):1114-1118.
128. Zhao R., Goldman I.D. Resistance to antifolates. Oncogene 2003, 22(47):7431-7457.
129. Zhao R., Goldman I.D. The molecular identity and characterization of a proton-coupled folate transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Reviews 2007, 26(1):129-139.
130. Zhao R., Matherly L.H., Goldman I.D. Membrane transporters and folate homeostasis: Intestinal absorption and transport into systemic compartments and tissues. Expert Reviews in Molecular Medicine 2009, 11:e4.
131. Zhao R., Min S.H., Qiu A., Sakaris A., Goldberg G.L., Sandoval C., et al. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 2007, 110(4):1147-1152.
132. Zhao R., Min S.H., Wang Y., Campanella E., Low P.S., Goldman I.D. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. The Journal of Biological Chemistry 2009, 284(7):4267-4274.
133. Zhao R., Qiu A., Tsai E., Jansen M., Akabas M.H., Goldman I.D. The proton-coupled folate transporter: Impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Molecular Pharmacology 2008, 74(3):854-862.
134. Zhao R., Russell R.G., Wang Y., Liu L., Gao F., Kneitz B., et al. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. The Journal of Biological Chemistry 2001, 276(13):10224-10228.
135. Zhao R., Shin D.S., Diop-Bove N., Ovits C.G., Goldman I.D. Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of function. The Journal of Biological Chemistry 2011, 286(27):24150-24158.
136. Zhao R., Shin D.S., Fiser A., Goldman I.D. Identification of a functionally critical GXXG motif and its relationship to the folate binding site of the proton-coupled folate transporter (PCFT-SLC46A1). American Journal of Physiology. Cell Physiology 2012, 303(6):C673-C681.
137. Zhao R., Unal E.S., Shin D.S., Goldman I.D. Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. Biochemistry (Moscow) 2010, 49(13):2925-2931.
138. Zhao R., Visentin M., Suadicani S.O., Goldman I.D. Inhibition of the proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and other anions. Molecular Pharmacology 2013, 84(1):95-103.